MedTrace Logo

SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial

NCT07421869 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2026-02-19

No results posted yet for this study

Summary

The goal of this study is to find out whether hypothyroidism caused by immune checkpoint inhibitors (ICIs) can recover after stopping the ICIs. The study also aims to identify factors that can help predict which patients will be able to stop taking thyroid hormone replacement.

The main questions the study will answer are:

* What percentage of patients recover normal thyroid function and can stop levothyroxine after stopping ICIs?
* What clinical or laboratory factors can predict successful withdrawal of levothyroxine?

Participants will:

* Be adult cancer patients who developed hypothyroidism during ICI treatment and are currently taking levothyroxine
* Have already stopped ICI therapy
* Gradually reduce their levothyroxine dose every 3 months if their thyroid function remains normal
* Stop levothyroxine if thyroid function remains normal at low doses (≤0.025 mg)
* Be monitored with thyroid function tests and clinical symptoms at each visit

Conditions

Interventions

DRUG

Levothyroxine tapering

Participants will undergo a gradual dose reduction of levothyroxine according to a standardized tapering protocol. The levothyroxine dose will be reduced every 3 months based on thyroid function test results. If thyroid function remains stable, the dose will be decreased by 0.025 mg (±0.0125 mg). If thyroid function remains stable at a low dose (≤0.025 mg), levothyroxine will be discontinued.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-12
Primary Completion
2029-03-04
Completion
2029-03-04

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07421869 on ClinicalTrials.gov